EIKN stock news · Eikon Therapeutics, Inc.
Get alerts for EIKN
Follow Eikon Therapeutics, Inc. (EIKN) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for EIKNFree on the App Store and Google Play, or on the web.
Eikon Therapeutics got the green light from the FDA to start testing EIK1006 on prostate cancer patients.
Good for EIKNEikon received FDA clearance to test EIK1006 in people. Dosing is expected in 2027, with early safety and benefit findings in the second half; this is positive for Eikon.
Eikon Therapeutics, Inc. shares new clinical data from its research at a big medical conference.
NeutralEikon reported early results from its cancer drug studies. Tumors shrank in some patients, but varied responses and frequent severe side effects leave its outlook unchanged for now.